Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 5, pp 1035–1044 | Cite as

Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals

Original Article
First Online:
Received:
Accepted:

Abstract

Purpose

Therapeutic inhibition of angiogenesis has a benefit in the treatment of neoplastic diseases. Cisplatin is a widely used anti-cancer agent; however, it has serious side effects on non-tumor cells and causes nephrotoxicity due to its reactive oxygen species–mediated effect. Thus, a combination between cisplatin and angiogenesis inhibitors may be useful in cancer treatment. In the present study, the effect of sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, on the antitumor activity as well as the nephrotoxic side effect of cisplatin was examined.

Methods

The antitumor activity was evaluated both in vitro using cultured Ehrlich ascites carcinoma (EAC) cells and in vivo using a mouse model of solid tumor. In addition, the effect of cisplatin and/or sunitinib on the angiogenic marker, VEGF, was examined. Nephrotoxicity was induced in rats by single i.p. injection of cisplatin (6 mg/kg).

Results

Sunitinib significantly potentiated the cytotoxic effect of cisplatin in vitro and in vivo. The nephrotoxicity of cisplatin was evidenced by decrease in the body weight, increase in kidney/body weight ratio and decrease in the percent survival of rats. The toxicity was also confirmed biochemically by measuring some kidney function parameters and oxidative stress markers. Sunitinib significantly decreased cisplatin-induced changes in serum creatinine, blood urea nitrogen, creatinine clearance and micro total protein in urine, renal malondialdehyde levels and reduced glutathione contents. In addition, sunitinib effectively blunted cisplatin-induced proximal and distal tubules necrosis.

Conclusion

The potential for sunitinib to ameliorate the cisplatin-evoked toxicity as well as to improve the chemotherapeutic effect could have beneficial implications for patients undergoing chemotherapy with cisplatin.

Keywords

Cisplatin Sunitinib Angiogenesis Ehrlich ascites carcinoma (EAC) Vascular endothelial growth factor (VEGF) Nephrotoxicity 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by grants from Mansoura University, Egypt. The funder has no role in study design, data collection and analysis or preparation of the manuscript. Disclosures: None.

References

  1. 1.
    Atessahim A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A (2005) Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicol 212:116–123CrossRefGoogle Scholar
  2. 2.
    Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH (2005) Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76:2125–2135PubMedCrossRefGoogle Scholar
  3. 3.
    Badary OA, Sharaby SA, Kenawy SA, El-Denshary EE, Hamada FM (2000) Evaluation of cisplatin combined with ondansetron in Ehrlich ascites carcinoma in vitro and in vivo. Tumori 86:153–156PubMedGoogle Scholar
  4. 4.
    Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV (1998) In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53:394–401PubMedCrossRefGoogle Scholar
  5. 5.
    Blokhina OB, Virolainen E, Fagerstedt KV, Hoikkala A, Wähälä K, Chirkova TV (2000) Antioxidant status of anoxia-tolerant and -intolerant plant species under anoxia and reaeration. Physiol Plantarum 109:396–403CrossRefGoogle Scholar
  6. 6.
    Bompart G (1989) Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. Toxicol Lett 48:193–199PubMedCrossRefGoogle Scholar
  7. 7.
    Boulikas T, Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drug. Oncol Rep 11:559–595PubMedGoogle Scholar
  8. 8.
    Cathcart RF 3rd (1985) Vitamin C: the nontoxic, nonrate-limited, antioxidant free radical scavenger. Med Hypotheses 18:61–77PubMedCrossRefGoogle Scholar
  9. 9.
    Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J (2004) Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 4:20PubMedCrossRefGoogle Scholar
  10. 10.
    Conklin KA (2000) Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37:1–18PubMedCrossRefGoogle Scholar
  11. 11.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRefGoogle Scholar
  12. 12.
    Courjault-Gautier F, Le Grimellec C, Giocondi MC, Toutain HJ (1995) Modulation of sodium-coupled uptake and membrane fluidity by cisplatin in renal proximal tubular cells in primary culture and brush-border membrane vesicles. Kidney Int 47:1048–1056PubMedCrossRefGoogle Scholar
  13. 13.
    Daniel WW (1991) Hypothesis testing. In: Biostatistics: a foundation for analysis in the health sciences, 5th edn. Wiley, New York, p 191Google Scholar
  14. 14.
    Draper HH, Hadley M (1990) Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 186:421–431PubMedCrossRefGoogle Scholar
  15. 15.
    Duque I, Garcia-Escribano C, Rodriguez-Puyol M, Diez-Marques ML, Lopez-Novoa JM, Arribas I, Hernando L, Rodriguez-Puyol D (1992) Effects of reactive oxygen species on cultured rat glomeruli. Am J Physiol 263:F466–F473PubMedGoogle Scholar
  16. 16.
    Ebos JM, Lee CR, Chritensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104:17069–17074PubMedCrossRefGoogle Scholar
  17. 17.
    EL-Azab MF, El-Awady E, Moustafa M, Abd El-Hamid S (2009) Effects of thalidomide, rofecoxib and captopril on vascular endothelial growth factor in Ehrlich ascites carcinoma. Haematologica 94:234 abs. 0572Google Scholar
  18. 18.
    Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMedCrossRefGoogle Scholar
  19. 19.
    Eskens FA, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42:3127–3139PubMedCrossRefGoogle Scholar
  20. 20.
    George D, Moore C (2006) Angiogenesis inhibitors in clinical oncology. Update Cancer Ther 1:429–434CrossRefGoogle Scholar
  21. 21.
    Goncalves S, Fernandez-Sanchez R, Sanchez-Nino MD, Tejedor A, Neria F, Egido J, Ruiz-Ortega M, Ortiz A (2010) Tyrphostins as potential therapeutic agents for acute kidney injury. Curr Med Chem 17:974–986PubMedCrossRefGoogle Scholar
  22. 22.
    Gulec M, Iraz M, Yilmaz HR, Ozyurtd H, Temel I (2006) The effects of ginkgo biloba extract on tissue adenosine deaminase, xanthine oxidase, myeloperoxidase, malondialdehyde and nitric oxide in cisplatin-induced nephrotoxicity. Toxicol Ind Health 22:125–130PubMedCrossRefGoogle Scholar
  23. 23.
    Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142:231–255 (review)PubMedCrossRefGoogle Scholar
  24. 24.
    Henry JB (1974) Todd Sanford Davidsohn: clinical diagnosis and management by laboratory methods, 16th edn. WB Saunders and Co., Philadelphia, p 260Google Scholar
  25. 25.
    Henry RJ, Cannon DC, Winkelman JW (1974) Clinical chemistry, principles and techniques, 2nd ed edn. Harper and Row, USA, p 525Google Scholar
  26. 26.
    Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P (2009) Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma. An in vitro and in vivo study. Oncol Rep 22:1237–1245PubMedGoogle Scholar
  27. 27.
    Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y (2004) The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 23:29–34PubMedCrossRefGoogle Scholar
  28. 28.
    Kellen M, Aronson S, Roizen MF, Barnard J, Thisted RA (1994) Predictive and diagnostic tests of renal failure: a review. Anesth Analg 78:134–142PubMedCrossRefGoogle Scholar
  29. 29.
    Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW (1995) Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376:785–788PubMedCrossRefGoogle Scholar
  30. 30.
    Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMedCrossRefGoogle Scholar
  31. 31.
    Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82PubMedCrossRefGoogle Scholar
  32. 32.
    Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480PubMedCrossRefGoogle Scholar
  33. 33.
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedCrossRefGoogle Scholar
  34. 34.
    Marklund SL (1985) Superoxide dismutase isoenzymes in tissues and plasma from New Zealand black mice, nude mice and normal BALB/c mice. Mutat Res 148:129–134PubMedGoogle Scholar
  35. 35.
    Masuda H, Tanaka T, Takahama UT (1994) Cisplatin generates superoxide anion by interaction with DNA in a cell free system. Biochem Biophys Res Commun 203:175–180CrossRefGoogle Scholar
  36. 36.
    Mueller PW, Lash L, Price RG, Stolte H, Gelpi E, Maack T, Berndt WO (1997) Urinary biomarkers to detect significant effects of environmental and occupational exposure to nephrotoxins. I. Categories of tests for detecting effects of nephrotoxins. Renal Fail 19:505–521CrossRefGoogle Scholar
  37. 37.
    Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baumc DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13:2643–2650PubMedCrossRefGoogle Scholar
  38. 38.
    Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRefGoogle Scholar
  39. 39.
    Oncu M, Gultekin F, Karaöz E, Altuntas I, Delibas N (2002) Nephrotoxicity in rats induced by chlorpryfos-ethyl and ameliorating effects of antioxidants. Hum Exp Toxicol 21:223–230PubMedCrossRefGoogle Scholar
  40. 40.
    Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848PubMedCrossRefGoogle Scholar
  41. 41.
    Raja Naresh RA, Ndupa N, Uma Devi P (1996) Effect of macrophage activation on niosome encapsulated bleomycin in tumor- bearing mice. Ind J Pharamcol 28:175–180Google Scholar
  42. 42.
    Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379PubMedGoogle Scholar
  43. 43.
    Schirner M, Hoffmann J, Menrad A, Schneider MR (1998) Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4:1331–1336PubMedGoogle Scholar
  44. 44.
    Shimeda Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T, Tanaka K (2005) Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull 28:1635–1638PubMedCrossRefGoogle Scholar
  45. 45.
    Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T (1989) Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun 159:1121–1127PubMedCrossRefGoogle Scholar
  46. 46.
    Sung MJ, Kim DH, Jung YJ, Kong KP, Lee AS, Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, Park SK (2008) Genistein protects the kidney from cisplatin-induced injury. Kidney Int 74:1538–1547PubMedCrossRefGoogle Scholar
  47. 47.
    To YF, Sun RW, Chen Y, Chan VS, Yu WY, Tam PK, Che CM, Lin CL (2009) Gold (III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int J Cancer 124:1971–1979PubMedCrossRefGoogle Scholar
  48. 48.
    Tsutsumishita Y, Onda T, Okada K, Takeda M, Endou H, Futaki S, Niwa M (1998) Involvement of H2O2 production in cisplatin-induced nephrotoxicity. Biochem Biophys Res Commun 242:310–312PubMedCrossRefGoogle Scholar
  49. 49.
    Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K (1986) Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32:1551–1554PubMedGoogle Scholar
  50. 50.
    Weisenthal LM, Dill PL, Kunick NB, Lippman ME (1983) Comparison of dye exclusion assays with a cologenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43:258–264PubMedGoogle Scholar
  51. 51.
    Yee MS, Blakley BW, Begleiter A, Leith M (2008) Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37:638–641PubMedGoogle Scholar
  52. 52.
    Yoshida M, Itzuka K, Hara M, Nishijima H, Shimada A, Nakada K, Satoh Y, Kama Y, Terada A (2000) Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku J Exp Med 191:209–220PubMedCrossRefGoogle Scholar
  53. 53.
    Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, Grenman R (2009) Concurrent cetuximab, cisplatin and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother-Oncol 92:388–392PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of Pharmacology and Toxicology, Faculty of PharmacyMansoura UniversityMansouraEgypt

Personalised recommendations